Investing.com – A study by biotech company Gilead Sciences Inc (NASDAQ: GILD) found that a short, 5-day course of treatment of moderately severe hospitalized patients with COVID-19 with experimental remdesivir was more effective than 10 days and than standard treatment, writes Market Watch.
The results of the third phase of the open-label studies were published in the American scientific journal of the medical association JAMA. The company has already received permission for emergency use of remdesivir, but only for critically ill patients with COVID-19. However, she continues to study the effect of the drug on patients with moderate severity and even on pregnant women.
The study involved 584 patients, of whom 193 were on a 10-day course of treatment, 191 on a 5-day course, and another 200 received standard care.
The study results “suggest moderate clinical benefit for a 5-day course of therapy compared to standard treatment,” although, as the authors admit, “the clinical relevance of this finding is questionable,” the JAMA article notes.
“Some of the differences in the results of [randomized controlled trials] of remdesivir may be due to differences in study design,” the authors believe.
Gilead shares are up 1.7% year-to-date, while the S&P 500 is up 6.2%.
– In the preparation, materials from Market Watch were used